Contributions
Abstract: PB1784
Type: Publication Only
Background
Studies of B-SLL published to date have included heterogeneous groups of patients(pts) and did not use modern diagnostic criteria, or included pts who had in fact chronic lymphocytic leukemia. Outside the context of clinical trials, SLL pts are treated heterogeneously and thus there are no data concerning the impact of different treatment approaches on response and survival. In the updated WHO classification it is pointed out that there are a subset of cases with lymph node(LN) involvement by SLL in which proliferation centers(PCs) were not observed and pts in whom lymphadenopathy was <1.5 cm showing a better prognosis
Aims
To: a)record clinical, biological features and treatment strategy in a series of SLL pts diagnosed in our centers b)correlate clinicopathological characteristics and treatment with response and survival c)detect possible differences in terms of response and survival between SLL pts according to LN characteristics (size of LN and presence of PCs)
Methods
Results
47 pts were analysed. Pts’ median age was 69y (range, 40–87) with no gender predominance (24male/23female). According to Binet staging system 12, 19 and 9 were classified as A, B and C stage respectively while according to Ann Arbor system 42(89%) had advanced disease stage. 11 pts presented with bulky lymphadenopathy, 11 had splenomegaly and 4 had B-symptoms. LN biopsies were performed in 37 out of 47 pts. All pts underwent bone marrow (BM) biopsy with a median BM infiltration of 45% (0-97%). PCs were identified in 19 out of 24 pts in whom data were available, while 31 pts were presented with LN > 1,5 cm as measured in CT. The estimated 10 y -OS was 60% while median TFS was 5,3 mos. Age and ECOG performance status were the only parameters that were statistically significant in terms of survival (p=0,019 and p=0,013 respectively). Pts with LN<1,5cm and pts in whom there were no detectable PCs tended to have better survival. 24 pts (51%) were in need of therapy and most of them were treated with mild immunochemotherapy [13 received Rituximab(R)-Chlorambucil(Chl), 3 RCVP, 2FCR, 1RBendamustine, 2 Chl, 2R as monotherapy and 1 received corticosteroids].23 pts were assessable for response and among them 4 entered CR,17 PR and one had stable disease.
Conclusion
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Abstract: PB1784
Type: Publication Only
Background
Studies of B-SLL published to date have included heterogeneous groups of patients(pts) and did not use modern diagnostic criteria, or included pts who had in fact chronic lymphocytic leukemia. Outside the context of clinical trials, SLL pts are treated heterogeneously and thus there are no data concerning the impact of different treatment approaches on response and survival. In the updated WHO classification it is pointed out that there are a subset of cases with lymph node(LN) involvement by SLL in which proliferation centers(PCs) were not observed and pts in whom lymphadenopathy was <1.5 cm showing a better prognosis
Aims
To: a)record clinical, biological features and treatment strategy in a series of SLL pts diagnosed in our centers b)correlate clinicopathological characteristics and treatment with response and survival c)detect possible differences in terms of response and survival between SLL pts according to LN characteristics (size of LN and presence of PCs)
Methods
Results
47 pts were analysed. Pts’ median age was 69y (range, 40–87) with no gender predominance (24male/23female). According to Binet staging system 12, 19 and 9 were classified as A, B and C stage respectively while according to Ann Arbor system 42(89%) had advanced disease stage. 11 pts presented with bulky lymphadenopathy, 11 had splenomegaly and 4 had B-symptoms. LN biopsies were performed in 37 out of 47 pts. All pts underwent bone marrow (BM) biopsy with a median BM infiltration of 45% (0-97%). PCs were identified in 19 out of 24 pts in whom data were available, while 31 pts were presented with LN > 1,5 cm as measured in CT. The estimated 10 y -OS was 60% while median TFS was 5,3 mos. Age and ECOG performance status were the only parameters that were statistically significant in terms of survival (p=0,019 and p=0,013 respectively). Pts with LN<1,5cm and pts in whom there were no detectable PCs tended to have better survival. 24 pts (51%) were in need of therapy and most of them were treated with mild immunochemotherapy [13 received Rituximab(R)-Chlorambucil(Chl), 3 RCVP, 2FCR, 1RBendamustine, 2 Chl, 2R as monotherapy and 1 received corticosteroids].23 pts were assessable for response and among them 4 entered CR,17 PR and one had stable disease.
Conclusion
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical